HTLF Bank Purchases New Holdings in Bristol-Myers Squibb (NYSE:BMY)

HTLF Bank acquired a new stake in Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 7,166 shares of the biopharmaceutical company’s stock, valued at approximately $368,000.

Other large investors also recently made changes to their positions in the company. True Wealth Design LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $26,000. Coppell Advisory Solutions Corp. acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $31,000. Coppell Advisory Solutions LLC acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $28,000. Live Oak Investment Partners acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $33,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $25,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on BMY shares. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Finally, Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Stock Up 1.3 %

Shares of BMY opened at $48.93 on Friday. The stock has a market capitalization of $99.17 billion, a price-to-earnings ratio of 12.68, a PEG ratio of 1.46 and a beta of 0.39. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The stock has a fifty day moving average of $51.23 and a 200-day moving average of $51.51.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. During the same period in the previous year, the business posted $1.82 earnings per share. The business’s quarterly revenue was up .6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.90%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.